Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial-Reference-Cited by-同舟云学术

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

Published:2024-09 Issue: Volume: Page:114327
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Eggermont Alexander MM,Kicinski Michal,Blank Christian U,Mandala Mario,Long Georgina V,Atkinson Victoria,Dalle Stéphane,Haydon Andrew,Meshcheryakov Andrey,Khattak Adnan,Carlino Matteo S,Sandhu Shahneen,Larkin James,Puig Susana,Ascierto Paolo A,Rutkowski Piotr,Schadendorf Dirk,Boers-Sonderen Marye,Di Giacomo Anna Maria,van den Eertwegh Alfonsus JM,Grob Jean-Jacques,Gutzmer Ralf,Jamal Rahima,van Akkooi Alexander C.J.,Lorigan Paul,Grebennik Dmitri,Kreplere Clemens,Marreaud Sandrine,Suciu Stefan,Robert Caroline

Publisher

Elsevier BV

Reference34 articles.

1. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial;Eggermont;Lancet Oncol,2015

2. Prolonged survival in Stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016

3. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial;Eggermont;Eur J Cancer,2019

4. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017

5. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol,2020